{"url_path":"/sec/snti/8-k/2026-05-14/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1854270/0001628280-26-034834-index.html","accession_number":"0001628280-26-034834","cik":"0001854270","ticker":"SNTI","issuer_name":"Senti Biosciences Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1854270/0001628280-26-034834-index.html","primary_entity_key":"0001854270","primary_entity_name":"Senti Biosciences Holdings, Inc."},"word_count":43,"has_tables":true,"body_markdown":"Item 8.01. Other Events\n\nOn May 14, the Company issued a press release announcing certain clinical data and regulatory interactions related to its product SENTI-202. A copy of the press release is being furnished as Exhibit 99.2 to this Report on Form 8-K."}